However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has ...
Oral GLP-1 drugs have been around for a few years, but formulations specifically for weight loss are new, and a new pill is ...
Treatment for diabetes and obesity is rapidly evolving, with multi-targeted approaches taking shape. Medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have set high ...
Adding tirzepatide helped patients shed pounds, improved complete skin clearance rates ...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, ...
Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...
How Gala GLP-1 Compounded Semaglutide, Tirzepatide, and Microdosing Options Work for Prescription Weight Management Without ...
Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is ...
New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that ...
SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs . The commercial potential tied to GLP-1 ...
Tirzepatide, the active ingredient behind the popular weight loss drug Zepbound and the diabetes drug Mounjaro, has more ...